The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms
Purpose of Review
Resistant gram-negative infections are becoming increasingly difficult to treat, prompting increased focus on drug development. This review will focus primarily on the new beta-lactam agents developed in the past 5 years that target multidrug-resistant (MDR) gram-negative organisms, including those producing carbapenemases.
Four new agents including ceftazidime-avibactam (CAZ-AVI), meropenem-vaborbactam (MER-VAB), imipenem-relebactam (IMI-REL), and cefiderocol have recently been approved for the treatment of resistant gram-negative infections. CAZ-AVI remains an option for blaOXA-48–producing isolates and potentially MDR Pseudomonas aeruginosa, but the concern for resistance arises when using the agent for KPC-producing Enterobacteriales. MER-VAB appears to be more stable than CAZ-AVI in the treatment of KPC-producing Enterobacteriales but less is known about its propensity for the development of resistance and the drug does not reliably expand the coverage of meropenem-resistant P. aeruginosa isolates. IMI-REL expands the spectrum of imipenem-cilastatin to include KPC-producing Enterobacteriales as well as MDR P. aeruginosa but much less is known about its real-world clinical utility. Cefiderocol is the only of the four new agents with efficacy against metallo-beta-lactamases and resistant Acinetobacter species, but comparator studies using best available therapy for carbapenem-resistant gram-negative bacterial infections show higher mortality rates with the new drug, making its role in clinical therapy still to be determined.
The new beta-lactams differ in their mechanisms of combatting resistance and thus have unique roles in therapy. Additional evidence is needed regarding the potential for development of resistance in the newer combination agents, as well as for the role of cefiderocol in carbapenem-resistant gram-negative infections.
KeywordsCarbapenem-resistant Enterobacteriales Ceftazidime-avibactam Meropenem-vaborbactam Imipenem-relebactam Cefiderocol
Compliance with Ethical Standards
Conflict of Interest
Dr. Noval declares that she has nothing to disclose. Dr. Banoub declares that she has nothing to disclose. Dr. Claeys received research support from GenMark Diagnostics and BioFire Diagnostics and has served as a speaker for Luminex Corporation and GenMark Diagnostics. Dr. Heil declares that she has nothing to disclose.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.CDC. The biggest antibiotic-resistant threats in the U.S. [Internet]. Centers for Disease Control and Prevention. 2019 [cited 2019 Oct 28]. Available from: https://www.cdc.gov/drugresistance/biggest-threats.html
- 3.Thaden JT, Li Y, Ruffin F, Maskarinec SA, Hill-Rorie JM, Wanda LC, et al. Increased costs associated with bloodstream infections caused by multidrug-resistant Gram-negative bacteria are due primarily to patients with hospital-acquired infections. Antimicrob Agents Chemother. 2017;61:e01709–16.PubMedPubMedCentralGoogle Scholar
- 6.Gallagher JC, MacDougall C. Antibiotics simplified. Fourth ed. Burlington: Jones & Bartlett Learning; 2018. 352 pGoogle Scholar
- 7.Tracking CRE | HAI | CDC [Internet]. 2019 [cited 2019 Oct 28]. Available from: https://www.cdc.gov/hai/organisms/cre/trackingcre.html.
- 9.Ceftazidime/avibactam [package insert]. Cincinnati, Ohio: Forest Laboratories; 2016.Google Scholar
- 10.Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016 Jun;16(6):661–73.CrossRefGoogle Scholar
- 12.Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;62(11):1380–9.CrossRefGoogle Scholar
- 13.Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;63(6):754–62.CrossRefGoogle Scholar
- 15.• Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61:e00883–17 Single-center study providing real-world clinical data supporting the use of ceftazidime-avibactam in comparison with best available therapy. PubMedPubMedCentralGoogle Scholar
- 17.Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2016;61:e02097–16.Google Scholar
- 19.Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. 2018. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2017;62:e02497–17.Google Scholar
- 22.Meropenem/vaborbactam [package insert]. Parsippany, NJ: The Medicines Company; 2017.Google Scholar
- 23.Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(11):e01443–17.Google Scholar
- 24.Mills J. Comparative in vitro activity of meropenem/vaborbactam and meropenem against a collection of real-world clinical isolates of Pseudomonas aeruginosa. [Internet]. Poster presented at: ID Week; 2019; Washington D.C.Google Scholar
- 25.Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018 Feb 27;319(8):788–99.CrossRefGoogle Scholar
- 26.• Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439–55 Open-label clinical study suggesting a potential advantage of MER-VAB compared with best available therapy for improved outcomes in CRE infections. CrossRefGoogle Scholar
- 27.Dudley M. New antibiotics: what’s in the pipeline. Presented at IDWeek; 2017. San Diego, CA.Google Scholar
- 28.Sabet M, Tarazi Z, Rubio-Aparicio D, Nolan TG, Parkinson J, Lomovskaya O, et al. Activity of simulated human dosage regimens of meropenem and vaborbactam against carbapenem-resistant Enterobacteriaceae in an in vitro hollow-fiber model. Antimicrob Agents Chemother. 2018;62(2):e01969–17.Google Scholar
- 30.Lomovskaya O, Lomovskaya O. Assessment of MIC increases with meropenem-vaborbactam and ceftazidime-avibactam in TANGO II (a phase 3 study of the treatment of CRE infections). Presented at IDWeek; 2017. San Diego, CA.Google Scholar
- 32.Commissioner of the FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections [Internet]. FDA. 2019 [cited 2019 Sep 19]. Available from: http://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-complicated-urinary-tract-and-complicated-intra-abdominal-infections
- 34.Lob SH, Hackel MA, Kazmierczak KM, Hoban DJ, Young K, Motyl MR, et al. In vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - results from the SMART global surveillance program. Diagn Microbiol Infect Dis. 2017 Jun;88(2):171–6.CrossRefGoogle Scholar
- 35.Schmidt-Malan SM, Mishra AJ, Mushtaq A, Brinkman CL, Patel R. In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant Gram-negative Bacilli. Antimicrob Agents Chemother. 2018;62(8):e00533–18.Google Scholar
- 38.Sims M, Mariyanovski V, McLeroth P, Akers W, Lee Y-C, Brown ML, et al. Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017;72(9):2616–26.CrossRefGoogle Scholar
- 40.Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60(12):7396–401. https://doi.org/10.1128/AAC.01405-16.CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Hsueh S-C, Lee Y-J, Huang Y-T, Liao C-H, Tsuji M, Hsueh P-R. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. J Antimicrob Chemother. 2019;74(2):380–6. https://doi.org/10.1093/jac/dky425.CrossRefPubMedGoogle Scholar
- 42.Tomaras AP, Crandon JL, McPherson CJ, Banevicius MA, Finegan SM, Irvine RL, et al. Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013;57(9):4197–207. https://doi.org/10.1128/AAC.00629-13.CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Katsube T, Wajima T, Ishibashi T, Arjona Ferreira JC, Echols R. Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob Agents Chemother. 2017;61(1). https://doi.org/10.1128/AAC.01381-16.
- 44.Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18(12):1319–28. https://doi.org/10.1016/S1473-3099(18)30554-1.CrossRefPubMedGoogle Scholar
- 46.Shionogi, Inc. Antimicrobial drugs advisory committee cefiderocol briefing document, NDA #209445. 2019. https://www.fda.gov/media/131705/download. Accessed 30 Oct 2019.
- 47.• Pogue JM, Bonomo RA, Kaye KS. Ceftazidime/avibactam, meropenem/vaborbactam, or both? Clinical and formulary considerations. Clin Infect Dis. 2019;68(3):519–24. Review and editorial describing the difference between CAZ/AVI and MER/VAB that summarizes the place of each agent in therapy. CrossRefGoogle Scholar